New PET scan could help track prostate cancer treatment success

NCT ID NCT04158245

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study looked at whether a special PET scan (18F-fluciclovine) can show how well treatments are working in men with advanced prostate cancer that no longer responds to hormone therapy. Nine men were given standard treatments like abiraterone, enzalutamide, or docetaxel. The PET scan was done before and 12 weeks after starting treatment to see if it could detect changes in the cancer better than regular CT or bone scans. The goal was to learn if this scan can help doctors monitor treatment response more accurately.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Tulane Cancer Center Clinic

    New Orleans, Louisiana, 70112, United States

Conditions

Explore the condition pages connected to this study.